-
公开(公告)号：US08053429B2
公开(公告)日：2011-11-08
申请号：US12553196
申请日：2009-09-03
IPC分类号： A61K9/00
CPC分类号： A61K9/0002 , A61K9/1617 , A61K9/2013 , A61K9/2054 , A61K9/2846 , A61K47/12
摘要： The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.
摘要翻译： 本发明涉及一种固体口服剂型，其包含与提高活性成分的生物利用度和/或吸收的增强剂组合的药物活性成分。 因此，固体口服剂型包括药物和增强剂，其中增强剂是中链脂肪酸酯，醚或盐或中链脂肪酸的衍生物，其优选在室温下为固体，并且其具有 碳链长度为6至20个碳原子。 优选地，固体口服剂型是控释剂型，例如延迟释放剂型。
-
公开(公告)号：US07820722B2
公开(公告)日：2010-10-26
申请号：US10145194
申请日：2002-05-13
申请人： Araz A. Raoof , Mangaraju Gudipati
发明人： Araz A. Raoof , Mangaraju Gudipati
IPC分类号： A61K47/12 , A61K31/727
CPC分类号： A61K9/0024 , A61K9/2013 , A61K9/4858 , A61K31/20 , A61K31/7088 , A61K38/00 , A61K47/12 , C12N15/113 , C12N15/1136 , C12N2310/315 , C12N2310/321 , A61K2300/00 , C12N2310/3525
摘要： A pharmaceutical composition comprising a drug and a permeation enhancer that comprises a multi-carbon backbone having a functional group and also one or more side chains which have one or more carbon atoms and, optionally, one or more functional groups.
摘要翻译： 一种药物组合物，其包含药物和渗透促进剂，其包含具有官能团的多碳主链和还具有一个或多个碳原子的一个或多个侧链，以及任选的一个或多个官能团。
-
3.发明授权公开(公告)号：US07513091B2
公开(公告)日：2009-04-07
申请号：US10566458
申请日：2004-07-30
申请人： Jagathesan Moodley
发明人： Jagathesan Moodley
CPC分类号： A61J3/074 , A61K9/0065
摘要： An automated process and apparatus for making a gastro-retentive device (10). The method includes the steps of providing a pouch assembly having an ingredient section within a membrane; folding the membrane to form a folded pouch assembly; inserting the folded pouch assembly into a first capsule section (20a) to form a pouch/first capsule assembly, and inserting the pouch/first capsule assembly into a second capsule section (20b). The process can further include the steps of providing a strip (32) of multiple pouch assemblies (18) and cutting a single pouch assembly from the strip (32).Also provided is an apparatus (38) for carrying out the above method which includes a tooling block (44) having a passageway (62) configured for slidable movement of the pouch assembly (18) therein, and a tooling pocket (60) extending from a top surface of the tooling block to the passageway and which receives the pouch assembly. A ram (86) is provided for pushing the pouch assembly through the tooling pocket into the passageway, wherein the pouch assembly is folded and encapsulated.
摘要翻译： 一种用于制造胃保持装置（10）的自动化方法和装置。 该方法包括以下步骤：提供在膜内具有成分部分的袋组件; 折叠膜以形成折叠的袋组件; 将折叠的小袋组件插入第一胶囊部分（20a）以形成袋/第一胶囊组件，并将袋/第一胶囊组件插入第二胶囊部分（20b）中。 该方法还可以包括提供多个袋组件（18）的条带（32）并从条带（32）切割单个袋组件的步骤。 还提供了一种用于执行上述方法的装置（38），其包括具有构造成用于其中的袋组件（18）的可滑动移动的通道（62）的工具块（44），以及工具袋（60），其从 工具块的顶表面到通道并且接收袋组件。 提供了一种冲头（86），用于将袋组件通过工具口推入通道中，其中袋组件被折叠和包封。
-
公开(公告)号：US08883203B2
公开(公告)日：2014-11-11
申请号：US12767076
申请日：2010-04-26
申请人： Thomas W. I. Leonard
发明人： Thomas W. I. Leonard
IPC分类号： A61K9/64 , A61K9/20 , A61K9/24 , A61K31/675 , A61K31/66 , A61K31/19 , A61K9/00 , A61K9/16 , A61K9/28 , A61K31/20 , A61K31/663 , A61K47/12
CPC分类号： A61K31/19 , A61K9/0053 , A61K9/1617 , A61K9/1635 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2846 , A61K31/20 , A61K31/663 , A61K31/675 , A61K47/12 , A61K2300/00
摘要： The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to enhance intestinal delivery of the bisphosphonate to the underlying circulation. Preferably, the enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms, and the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.
摘要翻译： 本发明涉及药物组合物和口服剂型，其包含双膦酸盐与增强剂的组合，以增强双膦酸盐向底层循环的肠输送。 优选地，增强剂是碳链长度为6至20个碳原子的中链脂肪酸或中链脂肪酸衍生物，并且固体口服剂型是缓释剂型，例如延迟释放剂型。
-
公开(公告)号：US08753683B2
公开(公告)日：2014-06-17
申请号：US12691927
申请日：2010-01-22
IPC分类号： A61K9/14
CPC分类号： A61K9/141 , A61K9/145 , A61K9/146 , A61K9/4833 , A61K9/4858 , A61K9/4866
摘要： A solid pharmaceutical composition comprising a water-soluble bioactive material and an encapsulating material which is present in the composition in the form of continuous solid phase, and in which solid particles of the bioactive material are dispersed and encapsulated in the continuous solid phase of the encapsulating material, wherein each of the bioactive material and the encapsulating material is normally a solid at room temperature and the melting point of the encapsulating material is lower than the melting point of the bioactive material, the bioactive material being preferably a bisphosphonate, most preferably alendronate, and the encapsulating material includes an enhancer, preferably a mono- or di-glyceride, or an encapsulating surfactant, preferably a polyoxyethylene/polyoxypropylene block copolymer having surface active properties, and a process for preparing the composition in which solid particles of the bioactive material are mixed with and dispersed in the encapsulating material which is in molten (liquid) form; and cooling the molten form of the encapsulating material to form a solid pharmaceutical composition having the solid particles of the bioactive material dispersed and encapsulated in a continuous solid phase of the encapsulating material.
摘要翻译： 一种固体药物组合物，其包含以连续固相形式存在于组合物中的水溶性生物活性材料和封装材料，其中生物活性材料的固体颗粒分散并包封在包封的连续固相中 材料，其中每个生物活性材料和包封材料在室温下通常为固体，并且包封材料的熔点低于生物活性材料的熔点，生物活性材料优选为双膦酸盐，最优选阿仑膦酸盐， 并且包封材料包括增强剂，优选单甘油酯或甘油二酯或包封表面活性剂，优选具有表面活性的聚氧乙烯/聚氧丙烯嵌段共聚物，以及制备其中生物活性物质的固体颗粒为 混合并分散在胶囊中 处于熔融（液体）形式的材料; 并且冷却包封材料的熔融形式以形成固体药物组合物，其具有将生物活性材料的固体颗粒分散并包封在封装材料的连续固相中。
-
公开(公告)号：US08323689B2
公开(公告)日：2012-12-04
申请号：US12172707
申请日：2008-07-14
CPC分类号： A61K9/0002 , A61K9/1617 , A61K9/2013 , A61K9/2054 , A61K9/2846 , A61K47/12
摘要： The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.
摘要翻译： 本发明涉及一种固体口服剂型，其包含与提高活性成分的生物利用度和/或吸收的增强剂组合的药物活性成分。 因此，固体口服剂型包括药物和增强剂，其中增强剂是中链脂肪酸酯，醚或盐或中链脂肪酸的衍生物，其优选在室温下为固体，并且其具有 碳链长度为6至20个碳原子。 优选地，固体口服剂型是控释剂型，例如延迟释放剂型。
-
7.发明申请METHOD FOR INDUCING A CELL-MEDIATED IMMUNE RESPONSE AND IMPROVED PARENTERAL VACCINE FORMULATIONS THEREOF 审中-公开用于诱导细胞介导的免疫应答的方法及其改良的外源性疫苗制剂公开(公告)号：US20080254134A1
公开(公告)日：2008-10-16
申请号：US12144130
申请日：2008-06-23
申请人： David J. Brayden
发明人： David J. Brayden
CPC分类号： A61K9/0019 , A61K9/0024 , A61K9/1647 , A61K39/099 , A61K2039/55555 , A61K2039/57 , Y10S530/825
摘要： A method of inducing either a TH1 polarised immune response, a TH2 polarised immune response or a combined TH1 and TH2 response to an antigen and associated vaccine formulations are disclosed. A method is provided for inducing a polarised TH1 response by parenteral administration of microparticles sized such that at least 50% of the microparticles are less than 5 μm, the microparticles containing antigen entrapped or encapsulated by a biodegradable polymer. Additionally, a method is provided for inducing a polarised TH2 response by parenteral administration of nanoparticles sized such that at least 50% of the nanoparticles are less than 600 nm, the nanoparticles containing antigen entrapped or encapsulated by a biodegradable polymer. Vaccine formulations containing the B. pertussis antigens PTd, FHA or a combination of PTd and FHA are provided.
摘要翻译： 诱导T 1 H 1偏振免疫应答，T H 2 H 2极化免疫应答或组合T H H 1和T H 1的极性免疫应答的方法， 公开了对抗原和相关疫苗制剂的反应。 提供了通过胃肠外给药微粒的尺寸使得至少50％的微粒小于5μm的微粒诱导极化的T H 1应答的方法，所述微粒含有被生物降解的包裹的抗原 聚合物。 此外，提供了一种通过胃肠外施用纳米粒子来诱导极化T H 2 H 2应答的方法，所述纳米颗粒的尺寸使得至少50％的纳米颗粒小于600nm，所述纳米颗粒含有被包被或被 可生物降解的聚合物。 提供含有百日咳杆菌抗原PTd，FHA或PTd和FHA的组合的疫苗制剂。
-
公开(公告)号：US08883201B2
公开(公告)日：2014-11-11
申请号：US12481952
申请日：2009-06-10
申请人： Thomas W. I. Leonard
发明人： Thomas W. I. Leonard
IPC分类号： A61K9/48 , A61K31/66 , A61K31/663 , A61K47/12 , A61K9/00 , A61K9/16 , A61K9/20 , A61K31/675 , A61K31/20 , A61K9/28 , A61K31/19
CPC分类号： A61K31/19 , A61K9/0053 , A61K9/1617 , A61K9/1635 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2846 , A61K31/20 , A61K31/663 , A61K31/675 , A61K47/12 , A61K2300/00
摘要： The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to enhance intestinal delivery of the bisphosphonate to the underlying circulation. Preferably, the enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms, and the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.
-
公开(公告)号：US08828431B2
公开(公告)日：2014-09-09
申请号：US13690082
申请日：2012-11-30
CPC分类号： A61K9/0002 , A61K9/1617 , A61K9/2013 , A61K9/2054 , A61K9/2846 , A61K47/12
摘要： The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.
摘要翻译： 本发明涉及一种固体口服剂型，其包含与提高活性成分的生物利用度和/或吸收的增强剂组合的药物活性成分。 因此，固体口服剂型包括药物和增强剂，其中增强剂是中链脂肪酸酯，醚或盐或中链脂肪酸的衍生物，其优选在室温下为固体，并且其具有 碳链长度为6至20个碳原子。 优选地，固体口服剂型是控释剂型，例如延迟释放剂型。
-
公开(公告)号：US07670626B2
公开(公告)日：2010-03-02
申请号：US10482081
申请日：2002-07-02
CPC分类号： A61K9/141 , A61K9/145 , A61K9/146 , A61K9/4833 , A61K9/4858 , A61K9/4866
摘要： A solid pharmaceutical composition comprising a water-soluble bioactive material and an encapsulating material which is present in the composition in the form of continuous solid phase, and in which solid particles of the bioactive material are dispersed and encapsulated in the continuous solid phase of the encapsulating material, wherein each of the bioactive material and the encapsulating material is normally a solid at room temperature and the melting point of the encapsulating material is lower than the melting point of the bioactive material, the bioactive material being preferably a bisphosphonate, most preferably alendronate, and the encapsulating material includes an enhancer, preferably a mono- or di-glyceride, or an encapsulating surfactant, preferably, a polyoxyethylene/polyoxypropylene block copolymer having surface active properties, and a process for preparing the composition in which solid particles of the bioactive material are mixed with and dispersed in the encapsulating material which is in molten (liquid) form; and cooling the molten form of the encapsulating material to form a solid pharmaceutical composition having the solid particles of the bioactive material dispersed and encapsulated in a continuous solid phase of the encapsulating material.
摘要翻译： 一种固体药物组合物，其包含以连续固相形式存在于组合物中的水溶性生物活性材料和封装材料，其中生物活性材料的固体颗粒分散并包封在包封的连续固相中 材料，其中每个生物活性材料和包封材料在室温下通常为固体，并且包封材料的熔点低于生物活性材料的熔点，生物活性材料优选为双膦酸盐，最优选阿仑膦酸盐， 并且包封材料包括增强剂，优选单甘油酯或甘油二酯或包封表面活性剂，优选具有表面活性的聚氧乙烯/聚氧丙烯嵌段共聚物，以及制备其中生物活性材料的固体颗粒的方法 混合并分散在胶囊中 处于熔融（液体）形式的材料; 并且冷却包封材料的熔融形式以形成固体药物组合物，其具有将生物活性材料的固体颗粒分散并包封在封装材料的连续固相中。
-
-
-
-
-
-
-
-
-
搜索结果
31 条记录 (耗时 0.022 秒)
